These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

818 related items for PubMed ID: 28596108

  • 21. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
    Yoshimura A, Yamada T, Okura N, Takeda T, Furutani W, Kubota Y, Shiotsu S, Hiranuma O, Nishioka N, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.
    BMC Cancer; 2018 Dec 11; 18(1):1241. PubMed ID: 30537950
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F.
    Oncotarget; 2017 Apr 04; 8(14):23020-23032. PubMed ID: 28416737
    [Abstract] [Full Text] [Related]

  • 23. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH, Soo RA.
    Drug Des Devel Ther; 2015 Apr 04; 9():5641-53. PubMed ID: 26508839
    [Abstract] [Full Text] [Related]

  • 24. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Yamaguchi O, Kaira K, Mouri A, Shiono A, Hashimoto K, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Kagamu H.
    Cancer Chemother Pharmacol; 2019 May 04; 83(5):817-825. PubMed ID: 30758646
    [Abstract] [Full Text] [Related]

  • 25. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
    Yoshida T, Tanaka H, Kuroda H, Shimizu J, Horio Y, Sakao Y, Inaba Y, Iwata H, Hida T, Yatabe Y.
    Lung Cancer; 2016 Oct 04; 100():14-19. PubMed ID: 27597275
    [Abstract] [Full Text] [Related]

  • 26. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q, Quan Q, Ding L, Hong X, Zhou N, Liang Y, Wu H.
    Oncotarget; 2015 Sep 22; 6(28):24904-11. PubMed ID: 26172562
    [Abstract] [Full Text] [Related]

  • 27. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
    Dal Maso A, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, Cecere FL, Del Conte A, Nardo G, Buoro V, Scattolin D, Monteverdi S, Urso L, Zulato E, Frega S, Bonanno L, Indraccolo S, Calabrese F, Conte P, Pasello G.
    Clin Lung Cancer; 2020 Jan 22; 21(1):1-14.e3. PubMed ID: 31601525
    [Abstract] [Full Text] [Related]

  • 28. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 22; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 29. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S.
    Clin Cancer Res; 2008 Nov 01; 14(21):7060-7. PubMed ID: 18981003
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Suda K, Murakami I, Sakai K, Tomizawa K, Mizuuchi H, Sato K, Nishio K, Mitsudomi T.
    Lung Cancer; 2016 Jan 01; 91():36-40. PubMed ID: 26711932
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC.
    J Clin Oncol; 2012 Feb 01; 30(4):433-40. PubMed ID: 22215752
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC.
    BMC Cancer; 2016 Nov 08; 16(1):868. PubMed ID: 27821111
    [Abstract] [Full Text] [Related]

  • 37. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Gou LY, Li AN, Yang JJ, Zhang XC, Su J, Yan HH, Xie Z, Lou NN, Liu SY, Dong ZY, Gao HF, Zhou Q, Zhong WZ, Xu CR, Wu YL.
    Oncotarget; 2016 Aug 09; 7(32):51311-51319. PubMed ID: 27259997
    [Abstract] [Full Text] [Related]

  • 38. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    Demuth C, Madsen AT, Weber B, Wu L, Meldgaard P, Sorensen BS.
    BMC Cancer; 2018 Feb 15; 18(1):191. PubMed ID: 29448920
    [Abstract] [Full Text] [Related]

  • 39. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
    Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K.
    Oncotarget; 2016 Sep 06; 7(36):58492-58499. PubMed ID: 27542267
    [Abstract] [Full Text] [Related]

  • 40. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
    Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, Minami D, Murakami T, Yokoyama T, Harada D, Kuyama S, Ichikawa H, Inoue K, Kishino D, Inoue M, Takigawa N, Shibayama T, Harita S, Tanimoto M, Kiura K.
    Clin Lung Cancer; 2017 Mar 06; 18(2):241-244. PubMed ID: 27506489
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.